New research published in Nature Communications shows another potential application for GLP-1 agonists, adding to established benefits in type 2 diabetes, obesi 30 May 2024
After more than 30 years with neuroscience-focused biopharma Neurocrine Biosciences, founder and chief executive Kevin Gorman is to retire in October—albeit sta 29 May 2024
Australia’s Neuren Pharmaceuticals has announced top-line results from its Phase II trial of NNZ-2591 in children with Pitt Hopkins syndrome (PTHS). 28 May 2024
SynaptixBio, a UK biotech that claims to be the world’s only company developing a therapy for TUBB4A-related leukodystrophies, has appointed Uwe Meya as chief m 23 May 2024
In an Expert View column.Bruce Leuchter.chief executive of Neurvati Neurosciences.a Blackstone Life Sciences portfolio company.outlines the importance of increa 17 May 2024
Jo Latimer.head of neurosciences and mental health at the UK’s Medical Research Council (MRC).has been appointed chief scientific officer at a charity performin 16 May 2024
Shares in Merck KGaA rose by around 4% in Wednesday’s trading after the Germany-based company presented its first quarter financial results and latest forecast 15 May 2024
A US Food and Drug Administration (FDA) panel will consider Lykos Therapeutics’ filing for midomafetamine capsules (MDMA) as a therapy-assisted treatment for po 15 May 2024
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.